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Despite their antiviral effect, the in vivo effect of inter-
ferons on HIV transmission is difficult to predict,
because interferons also activate and recruit HIV-
susceptible cells to sites of infection. HIV does not
normally induce type I interferons in infected cells,
but does if TREX1 is knocked down. Here, we inves-
tigated the effect of topical TREX1 knockdown and
local interferon production onHIV transmission in hu-
man cervicovaginal explants and humanized mice.
In explants in which TREX1 was knocked down,
HIV induced interferons, which blocked infection. In
humanized mice, even though TREX1 knockdown
increased infiltrating immune cells, it delayed viral
replication for 3–4weeks. Similarly intravaginal appli-
cation of type I interferons the day before HIV infec-
tion induced interferon responsive genes, reduced
inflammation, and decreased viral replication. How-
ever, intravenous interferon enhanced inflammation
and infection. Thus, inmodels of human sexual trans-
mission, a localized interferon response inhibits HIV
transmission but systemic interferons do not.
INTRODUCTION
Most viruses trigger expression of type I interferons (IFNs) when
pattern recognition receptors detect viral nucleic acids (Coccia
et al., 1994). IFNs orchestrate comprehensive antiviral gene
expression programs within infected cells and promote innate
and acquired antiviral immune responses by enhancing antigen
recognition, lymphocyte activation, and recruitment of immune
cells to infection sites. Acute infection with the HIV, however,
does not induce antiviral IFNs in the CD4+ T cells and macro-
phages that are productively infected (Goldfeld et al., 1991;
Unterholzner and Bowie, 2008; Yan et al., 2010). HIV evades im-
mune surveillance at multiple stages of the viral life cycle. During
viral entry, Toll-like receptor (TLR) RNA sensors do not recognizeCel
This is an open access article under the CC BY-NHIV genomic RNA, because most virions bypass endosomes
where these sensors are located. After fusion, genomic RNA is
shielded within the viral capsid from cytosolic RNA receptors.
HIV reverse transcripts are bound at both ends to HIV integrase,
which is predicted to interfere with recognition by cGAS, the
cytosolic DNA sensor. However, HIV reverse transcriptase (RT)
also generates incomplete reverse transcripts that are not bound
to integrase. These can trigger the cGAS-STING-IRF3 pathway
of IFN induction if they are not digested by TREX1, a ubiquitous
cytosolic 30–50 exonuclease (Cai et al., 2014; Gao et al., 2013;
Sun et al., 2013; Yan et al., 2009, 2010). When TREX1 is knocked
down or knocked out, in vitro HIV infection triggers type I IFN
expression in infected cells that inhibits viral replication. Type I
IFNs can also be induced by mutating the HIV capsid or
depleting host cofactors with which it interacts and by knocking
down SAMHD1 (Lahaye et al., 2013; Rasaiyaah et al., 2013;
Zhang et al., 2014).
Although IFNs have a strong and unequivocal antiviral effect
for most viruses, because HIV infects immune cells, the net ef-
fect of IFNs on HIV is more complicated. Type I IFNs block
both early and late stages of the HIV life cycle (Agy et al., 1995;
Coccia et al., 1994; Shirazi and Pitha, 1992). Although type I
IFNs also induce the expression of all known HIV restriction fac-
tors, including the APOBECs, SAMHD1, and tetherin, type I IFNs
can potentially enhance HIV infection by promoting T cell activa-
tion and recruiting HIV-susceptible cells to the site of infection.
Therefore, although in vitro experiments show that TREX1 defi-
ciency inhibits HIV replication, the in vivo consequences of
TREX1 knockdown are difficult to predict.
The antiviral effects of type I IFNs prompted researchers to
evaluate their administration as a treatment of HIV infection in
the early days of the HIV epidemic. Early studies showed clinical
improvement (H€ubner et al., 2007; Judge et al., 2005). These
promising results were replicated by two randomized control
studies, which demonstrated that IFNa treatment significantly
reduced viral loads in chronically infected patients (Jackson
et al., 2006; Saba et al., 2010). However, subsequent clinical tri-
als did not demonstrate similar therapeutic benefit (Fitzgerald-
Bocarsly and Jacobs, 2010; Lehmann et al., 2010; Swiecki and
Colonna, 2010). Researchers abandoned IFN-based therapiesl Reports 15, 1715–1727, May 24, 2016 ª 2016 The Author(s) 1715
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
when highly active antiretroviral therapy (HAART) became
widely available in the mid-1990s (Saba et al., 2010; Wu and
KewalRamani, 2006). IFNs, like other cytokines, are meant to
act locally at the site of infection and are probably most effective
at controlling viral infection when they are produced at high con-
centrations where the infection begins. The high concentrations
required for therapeutic benefit when exogenous IFN is adminis-
tered lead to systemic side effects, including fever, neutropenia,
and depression. The equivocal outcomes of systemic IFN treat-
ment may have been due, in part, to the nonspecific generalized
immune activation that accompanies sustained systemic IFN
administration. Knocking down TREX1 does not induce IFNs in
uninfected cells (Yan et al., 2010), providing a means to localize
IFN production to infected cells and evaluate whether IFNs pro-
duced in infected cells provide a net protective effect.
Here, we knock down TREX1 using CD4-aptamer-small inter-
fering RNA (siRNA) chimeras (CD4-AsiCs) in CD4+ cells in hu-
man cervicovaginal explants and in the genital tract of female
humanized mice to evaluate the effect on HIV transmission
of localized IFN production in infected cells. We previously
showed that CD4-AsiCs, which are composed of a CD4-target-
ing aptamer covalently linked to the passenger strand of an
siRNA and then annealed to the active strand, cause specific
gene knockdown in CD4+ T cells and monocytes/macrophages
without toxicity, cell activation, or innate immune off-target ef-
fects (Wheeler et al., 2011, 2013). Gene knockdown in tissue
lasts for almost 2 weeks (Collins et al., 2000; Wheeler et al.,
2011). Topical application of CD4-AsiCs designed to knock
down CCR5 and/or HIV gag and vif block vaginal transmission
in humanized mice.
Because studying early events in the sexual transmission of
HIV in humans is difficult, our understanding of sexual transmis-
sion of the virus relies heavily on studies inmacaques challenged
with cell-free simian immunodeficiency virus (SIV) (Arfi et al.,
2008; Bergamaschi and Pancino, 2010; d’Ettorre et al., 2014;
Miller et al., 2005; Piguet and Steinman, 2007). In this model,
SIV first infects and expands in CD4+ T cells in the genital mu-
cosa before spreading to myeloid cells (Haase, 2010; Miller
et al., 2005; Zhang et al., 1999). Infection is contained within
the genital tract for 1 week before disseminating to regional
lymph nodes and systemically. This provides a ‘‘window of op-
portunity’’ for interventions to prevent HIV from establishing a
foothold. Genital infection stimulates a pro-inflammatory cyto-
kine cascade, which recruits activated immune cells to the
genital mucosa (Caux et al., 2000; Dieu-Nosjean et al., 1999;
Miller et al., 2005), which then promotes viral replication and
spreading, both locally and systemically. Plasmacytoid dendritic
cells (pDCs), the primary producers of type I IFNs, are recruited
to the genital mucosa, but IFN production is delayed (Klatt et al.,
2014). Thus, because SIV does not induce IFNs in infected cells
and IFN production by recruited cells in the genital tract is de-
layed, SIV does not have to cope with the antiviral effects of
host IFNs while it is establishing the infection.
A recent study investigated the effect of manipulating type I
IFNs on transmission of repeated SIV rectal challenges in rhesus
macaques (Sandler et al., 2014). Blocking the type I IFN receptor
increased viral replication and AIDS progression, while adminis-
tration of IFN-a2a around the time of challenge blocked trans-1716 Cell Reports 15, 1715–1727, May 24, 2016mission. However, continued exposure to exogenous IFNs actu-
ally caused desensitization to its antiviral effect, increased the
viral setpoint, and accelerated disease progression. This work
highlights the potential protective role of type I IFNs but also sug-
gests that the in vivo effects of IFNs are complex.
Immune responses can differ between human and nonhuman
primates, since immune genes continue to coevolve with path-
ogens, and SIV differs in important ways from HIV. In particular,
the SIV viral protein Vpx promotes degradation of host restric-
tion factor SAMHD1, which limits HIV infection in resting
T cells and myeloid cells, thereby enabling SIV to replicate in
cell populations that HIV cannot. Given the complexity of the ef-
fects of IFNs, which activate components of the immune system
capable of both propagating and inhibiting HIV (Boasso et al.,
2008; Fitzgerald-Bocarsly and Jacobs, 2010; Hardy et al.,
2009; Poli et al., 1994), it is important to study the role of IFNs
in HIV transmission in human systems. In particular, the exact
role IFNs play in acute HIV infection, the timing of their induc-
tion, and the effects they exert on their most immediate down-
stream targets during the earliest stages of viral transmission
remain poorly understood. Here, we use two HIV-human trans-
mission model systems, polarized human cervicovaginal ex-
plants and humanized mice, to investigate the effect of inducing
type I IFNs in infected cells by TREX1 knockdown to assess the
effects of endogenous IFNs on HIV female genital transmission.
These models both have limitations. The explants are only
viable for 10–14 days (Collins et al., 2000; Wheeler et al.,
2011) and do not take into account recruitment of immune cells
to the tissue. Although human myeloid and lymphoid cells are
present in the female genital tract of humanized mice, they
are less abundant than in human tissues, and their lymph nodes
are often undeveloped or absent (Olesen et al., 2011). More-
over, humanized mice have chronic immune activation from
graft versus host responses. Although there is good cross-reac-
tivity between human and mouse cytokines and chemokines,
signaling may not replicate precisely what occurs in humans.
Nonetheless, these imperfect models are as close as we can
get to human transmission.
Here, we show that CD4-AsiCs knock down TREX1 expres-
sion by 75%–95% in human cervicovaginal tissue and the
female genital tract of humanized mice. Knocking down TREX1
increased expression of type I IFNs and interferon-stimulated
genes (ISGs) in HIV-exposed, but not uninfected, human tissue
and humanized mice in the first 12–24 hr after exposure, but
did not cause upregulation of inflammatory cytokines, such as
IL1b, IL-6, and IL-8. Intravaginal (IVAG) IFN administration had
a similar effect. In contrast, exogenous IFNs, given intravenously
(i.v.) to humanized mice, induced ISGs as well as proinflamma-
tory cytokine gene expression, even in the absence of HIV
infection. In tissue explants, TREX1 knockdown suppressed
HIV infection, and suppression was largely mediated by type I
IFNs, since it was strongly inhibited by neutralizing antibodies
to type I IFNs. In humanized mice, a robust type I IFN response
decreased viral replication during the first 48 hr after exposure,
despite recruitment of immune cells to the genital mucosa.
Importantly, TREX1 knockdown in the genital tract delayed HIV
infection for 3–4 weeks, suggesting that IFN induction in in-
fected cells suppresses local viral replication.
RESULTS
TREX1 Knockdown in CD4+ Cells In Vitro and in Human
Cervicovaginal Tissue Explants
CD4-AsiCs were designed to knock down TREX1 in CD4+ cells
using the CD4 aptamer and siRNA linkage, previously shown to
knock down CCR5 and viral genes selectively in CD4+ T cells
andmacrophages in cervicovaginal tissue explants and the gen-
ital tract of humanized mice (Wheeler et al., 2011, 2013). The ap-
tamer directs the chimeric RNA selectively intoCD4+ cells, where
Dicer cleaves the AsiC to separate the aptamer from the siRNA. A
chimeric RNA encoding the CD4 aptamer linked at its 30-end
to the sense strand of one of two TREX1 siRNAs was in vitro
transcribed using 20-fluoropyrimidines to enhance stability and
minimize off-target effects (Figures 1A and 1B). The in vitro tran-
scribed RNA was then annealed to the antisense siRNA strand.
To evaluate gene knockdown, peripheral blood mononuclear
cells (PBMCs) were incubated for 48 hr with 0.25–4 mM TREX1
CD4-AsiCs and analyzed by qRT-PCR for TREX1mRNA (Figures
1Cand1D).TREX1knockdownoccurred specifically inCD4+,but
not CD8+ T cells. The best knockdown occurred using 4 mMAsiC.
‘‘Sequencea,’’which knockeddownTREX1by50%evenat the
lowest concentration and by90% at the highest concentration,
was more effective than ‘‘sequence b’’ and was used for subse-
quent experiments, unless otherwise noted. TREX1 knockdown
in primary human CD4+ T cells also significantly reduced
TREX1 protein and the proportion of cells that stained above
background for TREX1 from 83% to 7%, as assessed by flow cy-
tometry (Figure S1).
Type I IFN signaling leads to phosphorylation and nuclear
translocation of the IRF3 transcription factor. To investigate
whether IFN signaling is activated after HIV infection in cells
knocked down for TREX1, we assessed IRF3 localization by im-
aging flow cytometry in primary human monocyte-derived mac-
rophages (MDMs) and CD4+ T cells (Figures S2A and S2E).
TREX1 knockdown did not significantly change IRF3 localization
in uninfected cells. However, as expected, IRF3 translocated to
the nucleus after HIV infection in cells knocked downwith TREX1
siRNA compared to cells transfected with a non-targeting nega-
tive control siRNA (MDMs, p < 0.01; CD4+ T cells, p < 0.0001). To
determine whether IRF3 activation is mediated by cGAS and
IFI16, DNA sensors that recognize HIV reverse transcripts (Gao
et al., 2013; Monroe et al., 2014), we co-transfected CD4+
T cells with TREX1 siRNA alone or together with cGAS or IFI16
siRNAs. siRNA targeting the DNA sensor AIM2 or the RNA
sensor RIG-I, which are not required for the induction of type I
IFN by HIV in TREX1 knockout cells (Yan et al., 2010), were
used as controls. Knockdown of cGAS or IFI16, but not AIM2
orDDX58, the gene encoding RIG-I, significantly and strongly in-
hibited IRF3 nuclear translocation in response to HIV infection
in TREX1 knocked down cells (Figures S2F–S2K). Thus, TREX1
knockdown induces IFN pathway activation and IRF3 nuclear
translocation in response to HIV that is dependent on DNA
sensing by both cGAS and IFI16, like recognition of HSV-1 and
Listeria monocytogenes DNA (Orzalli et al., 2015; Hansen
et al., 2014).
Next, we evaluated TREX1 gene knockdown in human cervi-
covaginal explants. TREX1CD4-AsiCs (1 and 4 mM)were appliedtwice at an interval of 24 hr to the epithelial surface of polarized
human cervicovaginal tissue. Four days after the second treat-
ment, tissues were digested to single cell suspensions, which
were sorted into CD4+/CD3+ T cells, CD4+/CD14+macrophages,
and CD19+ B cell subsets and analyzed for TREX1 mRNA by
qRT-PCR (Figures 1E and 1F). TREX1 was knocked down by
80%–95% in CD4+ T cells and macrophages, but not in B cells.
Both concentrations led to comparable knockdown. We previ-
ously showed that CD4-AsiCs targeting other genes do not acti-
vate an innate immune IFN response on their own (Wheeler et al.,
2011). However, because IFN induction may be sequence-
dependent, we evaluated whether TREX1-specific CD4-AsiCs
induce type I IFNs. We treated cervical explants with TREX1
CD4-AsiCs in the absence of HIV infection and measured
expression levels of type I IFN mRNAs in the tissue at the
expected peak response time (6 hr) by sensitive qRT-PCR
assay (Figure S3A). As expected, TREX1 CD4-AsiCs did not
induce an IFN response, whereas Poly(I:C), used as a positive
control, did.
TREX1 Knockdown Inhibits HIV Replication and Induces
IFN-b in Polarized Human Cervicovaginal Explants
TREX1 knockdown inhibits HIV expression in vitro by upregulat-
ing type I IFNs (Yan et al., 2010). To evaluate whether knocking
down TREX1 also inhibits HIV infection in human tissue, we
used a previously validated polarized human cervicovaginal
explant model of HIV transmission and infection. The observed
p24 Ag production in infected explants measured active viral
replication in the explants, rather than carryover of virus in the in-
fectious inoculum, since p24 Ag levels did not increase in tissues
that were infected in the presence of the HIV inhibitors, AZT, or
nevirapine (Figure S3B). To evaluate the effect of TREX1 knock-
down in the explant system, wemeasured viral replication in cer-
vicovaginal tissue from three healthy donors infected after they
were treated with PBS or CD4-AsiCs against TREX1 or, as
positive control, a cocktail against CCR5, gag, and vif. Explants
were treated 3 and 2 days prior to challengewith HIVBaL, and viral
replication was monitored by measuring viral p24 antigen in the
lower Transwell chamber (Figures 2A–2C). As previously demon-
strated, the CCR5 and antiviral gene cocktail completely pre-
vented productive HIV infection. CD4-AsiCs encoding either
TREX1 siRNA sequence inhibited HIV infection, but ‘‘sequence
a’’ performed better, almost completely suppressing p24 Ag
production. AlthoughHIV infection in the absence of gene knock-
down did not lead to detectable IFNb release until day 9 of cul-
ture, when it was barely above background, the infected tissues
that were treated with TREX1 AsiCs produced IFNb that was de-
tected in the first measurement on day 3 (Figure 2D). Tissues
treated with the more effective ‘‘sequence a’’ AsiC generated
more IFNb. Tissues treated with the CD4-AsiC cocktail that
blocked infection did not release IFNb. To evaluate the impor-
tance of type I IFNs in inhibiting HIV transmission in the tissue,
blocking monoclonal antibodies (mAbs) to IFNa and IFNb were
added to the culturemedium24 hr before and at the time of infec-
tion (Figures 2E–2G). The blocking antibodies had no effect on
HIV production in explants that were knocked down for CCR5
and the viral genes, which was not surprising since they did not
generate type I IFNs. Antibody treatment blunted the amount ofCell Reports 15, 1715–1727, May 24, 2016 1717
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Figure 1. CD4-AsiCs Knockdown TREX1 in
CD4+ Cells In Vitro and in Polarized Cervico-
vaginal Explants
(A and B) Two TREX1 CD4-AsiCs (sequence a, A;
sequence b, B).
(C and D) CD4+ (red) and CD8+ (blue) T cells were
treated and analyzed for TREX1 gene knockdown
by qRT-PCR relative to GAPDH. Experimental
schematic in (C). Relative TREX1 knockdown after
application of TREX1 CD4-AsiC sequence a (left)
and sequence b (right) is shown (D).
(E and F) CD4+CD14+ monocyte-derived macro-
phages (MDMs), CD4+ T cells, and CD19+ B cells,
sorted from polarized cervicovaginal explants
treated with TREX1 CD4-AsiCs, or PBS (mock),
were analyzed for TREX1 knockdown by qRT-
PCR. Graphs show mean ± SEM from three inde-
pendent experiments. *p < 0.05, **p < 0.005, ***p <
0.0005, by Student’s t test, relative to mock-
treated control samples. The change in TREX1 in
B cells was not reproducible. Experimental sche-
matic in (E). Relative TREX1 knockdown 4 d after
application of TREX1 CD4-AsiC sequence a or
PBS to MDMs (left), CD4+ T cells (middle) or
CD19+ B cells (right) is shown (F).
See also Figure S1.IFNb protein detected in the culture supernatants and increased
HIV infection in TREX1AsiC-treated explants. However, blocking
IFNa and IFNb in TREX1 AsiC-treated tissues did not completely
restore HIV infection to the level observed in tissues not sub-
jected to knockdown. Thus, TREX1 knockdown suppressed1718 Cell Reports 15, 1715–1727, May 24, 2016HIV infection in cervicovaginal tissues,
largely via induction of type I IFNs.
Recently transmitted HIV-1 viruses,
termed transmitted/founder (T/F) viruses,
are relatively resistant to suppression by
type I IFNs (Parrish et al., 2013). To deter-
mine whether TREX1 knockdown could
inhibit infection with T/F HIV-1 virus, we
compared the effect of TREX1 knock-
down on replication of a T/F virus relative
to HIVBaL in human cervical explants (Fig-
ure S4), using treatment with the CD4
aptamer on its own as a control. T/F HIV
replication was significantly inhibited by
treatment with TREX1 CD4-AsiCs. How-
ever, T/F virus was less strongly sup-
pressed than HIVBaL.
Exposure of MDMs to Type I IFN
Inhibits HIV Replication when
Administered Just before or after
Infection
To prepare for in vivo experiments with
IFNs, we first defined the dose-depen-
dence and timing of IFN protection from
HIV infection in vitro. MDMs were incu-
bated for 24 hr with different amounts ofa recombinant form of IFN, engineered to bind multiple IFN re-
ceptors with high affinity (rIFN), prior to infection with three doses
of HIVBaL (Figure S5). Adding 10,000 IU recombinant interferon
(rIFN) in 0.3 ml culture medium suppressed viral replication in
MDMs by >95% for even the highest viral challenge. At the
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Figure 2. CD4-AsiCKnockdown ofTREX1 Inhibits HIV Replication in Polarized HumanCervicovaginal Explants Partly by Inducing Type I IFNs
(A–D) Polarized explants (n = 8) from three donors treated with PBS (blue) or twice pretreated with 4 mM CD4-AsiCs targeting TREX1 (siRNA sequence a, light
green; siRNA sequence b, dark green) or CCR5, gag, and vif (cocktail, red) before HIV-1BaL challenge. Data for uninfected control cultures are shown in yellow.
Experimental schematic in (A). HIV infection analyzed by p24 Ag ELISA (B and C) and IFN-b protein measured by ELISA (D).
(E–G) Blocking monoclonal antibodies (mAbs) against IFN-a and IFN-b were applied 24 hr prior to and at the time of HIV challenge. Graphs show mean ± SEM.
*p < 0.05, **p < 0.005, ***p < 0.0005, by Student’s t test, relative to uninfected control. Experimental schematic in (E). Shown is a time course of p24 Ag (F) and
IFN-b (G) protein levels in the lower chamber after HIV infection.
See also Figures S2, S3, and S4.
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highest concentration, rIFN completely prevented viral replica-
tion when added up to 24 hr prior to or within 6 hr after viral chal-
lenge. At the lower doses, adding the recombinant protein 6 hr
before infection was more effective than adding it 24 hr before
infection. When rIFN was added 2 days before or 1 day after viral
challenge, there was little protection.
TREX1 Knockdown IVAG or Topical rIFN Upregulate
ISGs and Inhibit Early HIV Replication in Humanized
BLT Mice
To investigate the in vivo effect of TREX1 expression on HIV
transmission, we treated humanized BLT mice IVAG with PBS
or 40 pmol of TREX1 CD4-AsiCs on 2 consecutive days. Half
of the mice were not exposed to HIV and half were challenged
the following day with HIV1JR-CSF using a viral dose that repro-
ducibly infects all control mice (n = 6) (Wheeler et al., 2011,
2013) (Figure 3A). Additional groups of mice (n = 6) were treated
with i.v. rIFN (104 IU) or IVAG rIFN (23 103 IU) the day before viral
challenge. One hour post-rIFN administration, wemeasured rIFN
levels in the serum. After i.v. injection, rIFN was detected in the
serum at a level of 43.5 ± 0.57 IU/ml (n = 3), but it was not detect-
able in the serum after IVAG application (data not shown). Mice
were sacrificed 16 hr after viral challenge, and cervicovaginal tis-
sue was digested into single cell suspensions. Systemic IFN
significantly increased the number of human CD45+ hematopoi-
etic cells in the female genital tract, irrespective of HIV infection,
while TREX1 knockdown and topical IVAG IFN increased human
infiltrating cells in the genital tract only following HIV infection
(Figure 3B). Gene expression was examined in human CD45+
hematopoietic cells, human CD4+ cells, and in the total mixed
cell population isolated from the vaginal mucosa by qRT-PCR.
TREX1 CD4-AsiCs strongly knocked down TREX1 mRNA (by
95%) in genital tract CD4+ cells in both HIV uninfected and
infected mice (Figure 3C). Both topical and systemic IFNs
significantly increased CCR5 and IFN-responsive TREX1 and
APOBEC3G and other ISG mRNAs in tissue CD4+ cells (Figures
3C, 3H, 3I and 3K). In the absence of HIV infection, TREX1
knockdown did not significantly change expression of inflamma-
tory cytokines, CCR5, type I and II IFNs, or ISGs, including
SAMHD1 and APOBEC3G (Figures 3E–3J).
After HIV challenge, HIV gagmRNAwas detected above back-
ground in control and IFN-treated BLT mouse genital tissue, but
was not detected in mice treated with TREX1 AsiCs at this early
time point (Figure 3D). Thus, TREX1 knockdown was protective.Figure 3. TREX1 Knockdown or Topical IFN Upregulate ISGs and Inhib
(A) Schematic. BLT mice (n = 6 per treatment group) were treated twice IVAG wit
(dark red) or 2 3 103 IU IVAG (light red). Half of the mice in each group (n = 3) w
sacrificed 16 hr after that. Cervicovaginal tissue was digested to a single cell sus
(B) Flow cytometry analysis of human CD45+ cells in the vaginal tissue of each g
(C–E)RNA fromsortedcellsor total tissuewasanalyzed formRNA levelsbyqRT-PC
vaginal CD45+ cells (E) are shown. Human genemRNA levels, relative to GAPDHm
whichwas not detected (ND) in uninfected samples, was normalized toGAPDHmR
t test relative to PBS control. The graphs represent data from one experiment with
(F–K) mRNA levels for human inflammatory cytokines TNFA (F) and IL1B (G), HIV r
ISGs (J and K) in vaginal tissue are shown. mRNA levels, relative to GAPDH mRN
the mean ± SEM for each group. *p < 0.05 by two-sided Student’s t test, relative
prepared with human hematopoietic stem cells from one donor.
See also Figure S5.TREX1 knockdown, and to a greater extent topical and systemic
IFNs, also increased CCR5 mRNA in CD4+ cells in the genital
tissue, likely due to infiltration of activated immune cells and acti-
vationof tissue residentcells (Figures3Band3E).Withexposure to
HIV, TREX1 knockdown led to significantly increased type I and
type II IFNs and ISGmRNAs, including the mRNAs for the HIV re-
striction factor ISGs, SAMHD1 and APOBEC3G (Figures 3H–3J).
TREX1 knockdown did not have a consistent effect on HIV-
induced inflammatory gene expression—it significantly increased
TNFa, reduced IL-1b and IL-8, and did not change IL-6 mRNA
expression. Thus, early after HIV infection, TREX1 knockdown in
CD4+ cells in the female genital tract reduced HIV load and
induced IFNs and antiviral gene expression, but at the same
time, increased recruitment of activatedCCR5+ immune cells, ex-
panding the numbers of susceptible cells in the tissue.
Topical, but not systemic, IFN significantly suppressed early
HIV replication, assessed by measuring gag mRNA 16 hr after
infection, compared to control mice, but inhibition was less
effective than TREX1 knockdown, which suppressed HIV to un-
detectable levels (Figure 3D). Systemic rIFN more potently
induced ISG expression than TREX1 knockdown, but also
enhanced tissue recruitment of CCR5+ hematopoietic cells and
caused more pro-inflammatory gene expression. The recruit-
ment of activated HIV-susceptible cells and induction of inflam-
mation in the genital tract after systemic IFN administration may
have canceled the antiviral effects of ISGs on HIV replication.
TREX1CD4-AsiCsUpregulateGeneExpression of Type I
IFNs and ISGs in the Vaginal Tissue of HIV-Exposed
Humanized BLT Mice
Next, we evaluated the effect of TREX1 knockdown on gene
expression in the female genital tract of humanized mice 24 and
48 hr after viral challenge (Figure 4A). Mice treated IVAG with
TREX1 AsiCs were compared to mice treated IVAG with PBS as
negative control, or lipopolysaccharide (LPS), which induces
both type I IFNs and inflammatory cytokines, as positive control.
Each group was treated on 2 consecutive days and challenged
with HIV IVAG on the following day. Blood and cervicovaginal tis-
sue were harvested 24 and 48 hr later, single cell suspensions
were prepared, and human CD4+, human CD45+, and total cell
populations were analyzed for mRNA expression by qRT-PCR
(Figures 4C–4I). IVAG LPS, as expected, increased the numbers
of human CD45+ cells in the vaginal tissue (Figure 4B). TREX1
AsiCs knocked down TREX1 in CD4+ cells in the genital tract byit HIV Transmission in Humanized Mice
h PBS (blue) or 40 pmol TREX1 CD4-AsiCs (green) or once with rIFN 104 IU IV
ere challenged 24 hr after the last treatment with HIVJR-CSF, and all mice were
pension and sorted into human CD45+ and CD4+ cell populations.
roup of mice.
R.TREX1 (C) andHIVgag (D)mRNA in vaginalCD4+cells andCCR5expression in
RNA, were normalized to the value in the HIV-uninfected, PBS control. gagRNA,
NA. Shown are themean± SEM for each group. *p < 0.05 by two sidedStudent’s
BLT mice prepared with human hematopoietic stem cells from one donor.
estriction factors SAMHD1 (H) and APOBEC3G (I, A3G) and a panel of IFNs and
A, were normalized to the value in the HIV-uninfected, PBS control. Shown are
to PBS control. The graphs represent data from one experiment with BLT mice
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90% at 24 hr and 75% at 48 hr post challenge, while IVAG LPS
significantly increased the expression of IFN-responsive TREX1
in CD4+ cells in vaginal tissue at both time points and in the
blood significantly at 48 hr (Figure 4C). HIV infection in genital
tract CD4+ cells was suppressed to near background levels by
TREX1 knockdown at both time points, while LPS pretreatment
enhanced gag mRNA expression in the genital tract. (Figure 4D).
Unexpectedly, HIV gag mRNA was detected in blood CD4+ cells
of some LPS-treated mice at 48 hr, suggesting that infection may
not be restricted to the genital tract in the setting of genital inflam-
mation. However, because gag detection in blood cells was just
above background, this finding needs to be interpreted with
caution.CCR5mRNA, an indicator of T cell activation, was signif-
icantly decreased in vaginal and blood CD4+ cells in TREX1 AsiC-
treated mice, while it was significantly increased in LPS-treated
mice in both compartments compared to mock-treated, HIV-in-
fected mice (Figure 4E). Knockdown of TREX1 increased the
expression of type I IFNs and ISGs and decreased expression
of proinflammatory cytokines in tissue and blood, while LPS pre-
treatment increasedboth inflammation and the IFN response (Fig-
ure 4F–4I). Thus, TREX1 knockdown in genital CD4 cells, which
enhanced antiviral IFN gene expression and suppressed inflam-
mation, blocked HIV infection at 24 hr and significantly controlled
it to near background levels at 48 hr. Generalized innate immune
activation by LPS administration in the genital tract enhanced HIV
replication locally and accelerated dissemination.
TREX1 CD4-AsiCs Delay, but Do Not Prevent,
Transmission of HIV to Humanized BLT Mice
To evaluate the net antiviral effect of TREX1 knockdown, we
compared HIV infection and CD4+ T cell depletion in humanized
mice treated IVAG with TREX1 AsiCs with mock-treated mice
and mice treated with the AsiC cocktail against CCR5 and viral
genes that blocks viral transmission (Wheeler et al., 2011,
2013) (Figure 5A). (The control group data were previously pub-
lished in Wheeler et al. [2011], but the TREX1 knockdown data,
obtained at the same time, were not previously published.) All
mock-treated mice became infected and showed profound
CD4+ T cell depletion (Figures 5B–5E). Viremia was first detected
3–4 weeks post-challenge, CD4 counts began to drop within
2 weeks, and CD4+ T cells were severely depleted in all mice
by 8 weeks. Mice treated with the cocktail were not infected—
they had undetectable viremia, assessed by HIV p24 Ag and
HIV gag mRNA, and no change in CD4+ T cell counts. MiceFigure 4. TREX1 CD4-AsiCs Upregulate Type I IFNs and ISGs and Inhi
(A) Schematic. BLT mice (n = 6 per treatment group) were treated twice with IVA
infected with HIVJR-CSF. Blood and cervicovaginal tissues were obtained at sacrifi
genital tract single cell suspensions were either not sorted or sorted into human
(B) Flow cytometry analysis of human CD45+ cells in the tissue (left) and blood (r
(C–E) mRNA levels relative to humanGAPDHwere analyzed by qRT-PCR for huma
cells in genital tract (left) and blood (right). Human genemRNA levels were normali
GAPDH. ND, not detected. All graphs showmean ±SEM. *p < 0.05 relative to PBS
from one experiment using BLT mice prepared with human hematopoietic stem
(F–I) mRNA levels were analyzed by qRT-PCR onRNA extracted from genital tract
TNFA (F), IL1B (G), and a panel of IFNs, inflammatory cytokines, and ISGs (H and I
All graphs showmean ±SEM. *p < 0.05 relative to PBS-treated control mice, deter
BLT mice prepared with human hematopoietic stem cells from one donor.
See also Figure S5.treated with TREX1 AsiCs initially looked like they were pro-
tected, but they all developed detectable viremia by 7 weeks.
CD4+ T cell depletion only became significant after 9 weeks.
Thus, viral production was delayed for 1 month by knocking
down TREX1 prior to viral challenge compared to control mice.
Despite the delay in infection, the viral setpoint in TREX1 AsiC-
treated mice (105 copies/ml blood) and extent of CD4+ T cell
depletion at 12 weeks, when the experiment was terminated,
were indistinguishable from those in control mice.
DISCUSSION
Here, we demonstrate that TREX1 knockdown using CD4-AsiCs
induces expression and secretion of type I IFNs and ISGs in HIV-
infected cells that inhibits HIV transmission in human tissue
explants and in humanized mice for several weeks when admin-
istered prior to viral challenge. Protection from HIV replication in
tissue explants was largely abrogated by IFNa/b blocking anti-
bodies, suggesting that protection is mediated by type I IFN pro-
duction in infected cells. The residual protection may have been
due to incomplete blockade of all type I IFNs. We also cannot
exclude the possibility that some antiviral effects of TREX1
knockdown are IFN-independent. Indeed, ISGs can be induced
in the absence of TREX1 independently of IFNs (Hasan et al.,
2013). Within the first 2 days after HIV challenge, HIV replication
was not detected in the genital tract of mice treated with TREX1
CD4-AsiCs and was suppressed in mice given rIFN IVAG, sug-
gesting that local IFNs strongly inhibit HIV transmission in vivo.
This was despite evidence of significant immune cell infiltration
in the genital mucosa and CD4+ T cell activation to express
CCR5, the HIV coreceptor used during sexual transmission. In
contrast, i.v. administration of rIFN using five times the IVAG
dose, which induced local IFN and ISG gene expression in the
genital mucosa, but less robustly than IVAG administration, did
not inhibit HIV replication at this early time point. Unlike treatment
with IVAG IFN or TREX1-AsiCs, i.v. IFN activated proinflamma-
tory cytokine expression (TNFa, IL-1b, IL-6, and IL-8), which likely
counteracted the protective effects provided by rIFN.
In some humanized mice (but not those treated with TREX1
CD4-AsiCs), we detected HIV gag RNA at very low levels in
CD4+ blood cells as early as 1 and 2 days following IVAG
challenge, accompanied by suggestions of systemic immune
activation by qRT-PCR analysis of CCR5 and cytokine gene
expression in CD4+ blood cells (Figure 4D). Importantly, at thesebit HIV Transmission to BLT Mice
G PBS (blue), LPS (red), or 40 pmol TREX1 CD4-AsiCs (green). All mice were
ce 24 hr and 48 hr (n = 3 per treatment group) after viral challenge. PBMCs or
CD45+ and human CD4+ cell populations for analysis as indicated.
ight).
n TREX1 (C), HIV gag (D), and humanCCR5 (E) using RNA extracted fromCD4+
zed to the value in the HIV-uninfected, PBS control. gagRNAwas normalized to
-treated control mice determinedwith a Student’s t test. Graphs represent data
cells from one donor.
single cell suspensions or PBMCs as indicated for the following human genes—
). mRNA levels were normalized to the value in the HIV-uninfected, PBS control.
mined using Student’s t test. Graphs represent data from one experiment using
Cell Reports 15, 1715–1727, May 24, 2016 1723
AB
C
D
E
Figure 5. TREX1 CD4-AsiCs Delay HIV Transmission to BLT Mice
(A–D) Experimental design indicated in schematic in (A). Mice (n = 4 per treatment group) were treated according to the indicated dosing schedules (right) with
PBS (blue, B), a cocktail of CD4-AsiCs targeting CCR5, gag and vif, using a regimen that previously blocked HIV transmission (red, C) (Wheeler et al., 2011), or
TREX1 CD4-AsiCs (green, D). A total of 40 pmol of each CD4-AsiC was administered IVAG twice according to the dosing schedule. Mice were assessed for HIV
(legend continued on next page)
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early times, systemic dissemination was exacerbated by IVAG
pretreatment with LPS, which caused both local and systemic
IFN induction and immune activation. A similar increase in sexual
transmission was observed when rhesus macaques treated
IVAG with other TLR agonists were challenged with SIV (Wang
et al., 2005). In that case as well, both IFNs and inflammatory cy-
tokines were induced in the genital tract. However, infected cells
were not detected in the blood of mice treated IVAG with CD4-
AsiCs against TREX1. These data suggest that in humanized
mice, HIV may not be contained within the genital tract for the
first week after exposure. Nonetheless, we did not detect plasma
viremia by RT-PCR or p24 Ag assay until 3 weeks after infection
(Figure 5). Because the level of gag mRNA in circulating CD4+
T cells was just above background, the measured gag mRNA
in circulating CD4+ T cells within the first few days after infection
should be interpreted with caution and needs to be confirmed.
The discrepancy between RT-PCR analysis of CD4+ T cells
and plasma viremia assays suggests that RT-PCR analysis of
circulating CD4+ T cells may be a more sensitive way to detect
systemic dissemination than amplification of viral RNA in circu-
lating virions in the serum. Early dissemination might be the
consequence of chronic low levels of immune activation from
graft versus host responses that are not completely suppressed
in the NOD/SCID/Il2rg–/– (NSG) mice. Their chronic immune acti-
vation maymean that conclusions about transmission in human-
ized mice may not reflect transmission in women, who have no
underlying immune activation or vaginal coinfection. However,
these mice may be a good model for women with vaginal infec-
tions, such as bacterial vaginosis or trichomonas infection, who
are more vulnerable to becoming infected. If these mouse find-
ings are confirmed, they suggest that it is worth investigating
whether early viral dissemination might occur in women with
ongoing vaginal or systemic infection.
Although TREX1 knockdown suppressed HIV infection
early on, HIV was transmitted with a delay in viral kinetics of
3–4 weeks. In these experiments, TREX1 CD4-AsiCs were
administered 1 and 2 days before viral challenge. In an earlier
study (Wheeler et al., 2013), CCR5 knockdown in humanized
mice using CD4-AsiCs provided complete protection from trans-
mission when HIV challenge occurred within a day of AsiC appli-
cation, but although gene knockdown in the tissue persisted for
2 weeks, protection was incomplete when HIV challenge was
delayed for 4 or 6 days. The lack of complete protection after de-
layed challenge was attributed to influx of HIV-susceptible cells,
not exposed to AsiCs, into the genital mucosa. Similarly, in this
study, HIV might have persisted in the tissue (possibly within
myeloid cells that do not necessarily replicate the virus, but effi-
ciently transmit it to T cells) (Arfi et al., 2008; Bergamaschi and
Pancino, 2010; Kumar et al., 2014; Piguet and Steinman, 2007)
and then replicated in tissue resident CD4+ cells in which
TREX1 knockdown had waned or in recruited CD4+ T cells that
were not present at the time of knockdown. Although the knock-
down of TREX1 only delayed the progression of HIV infection,RNA by qRT-PCR (left), plasma HIV p24-Ag by ELISA (middle), and circulating
threshold of detection of the assay. No CD4 analysis was performed at week 4.
(E) shows average ±SEM for each group. *p < 0.05; ***p < 0.005, ***p < 0.0005, by o
two independent experiments with different batches of BLT mice prepared withbut did not inhibit it completely, the suppression of local HIV
replication in the genital tract might reduce person-to-person
transmission. Future experiments in which TREX1 AsiCs are
administered both before and after HIV challenge should
address this question. By measuring viral DNA species and inte-
gration of the provirus within different human cell subtypes in the
genital tract of humanizedmice, wemay be able to determine the
cell types in which the virus persists during TREX1 knockdown.
The viral setpoint and CD4 depletion in TREX1 knocked down
mice eventually reached the same levels as in mock-treated
mice. This surprising finding suggests that the viral setpoint is
not determined by the original viral replicative burst, but by the
complex interaction of the virus with the host immune system.
The conservation of the viral setpoint here may be related to
the well-known and poorly understood clinical finding that viral
levels return to the pretreatment setpoint when antiretroviral
drugs are halted. What determines the viral setpoint in any
setting is not well understood.
The in vitro data presented here suggest that there is a narrow
temporal window during which IFNs can effectively control infec-
tion—the 30 hr around the time of exposure. Our results echo
those found in SIV infection in macaques, in which IFN only effec-
tively blocks infection within a 3-day period (Unterholzner and
Bowie,2008).Thismaybeoneof the reasons thatchronic IFN ther-
apy showed inconsistent results in clinical trials and ultimately did
not appreciably improve patient outcomes (Fitzgerald-Bocarsly
and Jacobs, 2010; Jackson et al., 2006; Lehmann et al., 2010;
Saba et al., 2010; Swiecki and Colonna, 2010). In addition to
timing, location also seems to play a critical role. IFNs at the site
of transmission provided protection, but after systemic IFN treat-
ment, protection was lost, likely due to a shift in balance between
protective and harmful IFN-triggered downstream events. Our
finding in humanizedmicediffers from results inmacaques,where
i.v. PEGylated-IFN, begun before SIV challenge and continued for
4 weeks, provided protection from rectal challenge (Unterholzner
and Bowie, 2008). Multiple variables could account for these
differing observations including differences between species,
site of infection, virus, and dose and type of rIFN.
This study uses in vivo gene knockdown as a tool to explore
the earliest stages of HIV disease pathogenesis and the role
IFNs play in transmission. Knockdown of individual host genes
in all the cells that HIV infects using CD4-AsiCs provides a
straightforward method to explore the role of individual host
genes in HIV transmission. Preliminary results suggest that the
CD4-aptamer also recognizes macaque CD4 (data not shown).
Thus, this tool could also be used to study the role of host genes
in SIV transmission in macaques, where gene knockout is
not easy. We have recently found that EpCAM-AsiCs given
subcutaneously can silence gene expression in EpCAM+ cells
distributed at distal sites throughout the mouse (Gilboa-Geffen
et al., 2015). Preliminary studies of subcutaneous injection of
CD4-AsiCs in humanized mice also show strong knockdown
(80%) in CD4+ T cells in local lymph nodes, as well as in theCD4+ T cell count by flow cytometry (right). The dashed line represents the
ne-way ANOVA, relative to PBS control. The graphs represent data from one of
human hematopoietic stem cells from two different donors.
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spleen and distal lymph nodes. These findings suggest that this
powerful tool could be used to study the influence of individual
host genes not only on transmission, but also on disease pro-
gression and pathogenesis.
EXPERIMENTAL PROCEDURES
CD4-AsiC Synthesis
CD4-AsiCswere synthesized using the primer sequences given in Table S1 us-
ing in vitro transcription as described (Davis et al., 1998; McNamara et al.,
2006; Wheeler et al., 2011). Sequences for the conjugated siRNAs are shown
in Table S2.
Human Cervical Polarized Tissue Explants
Human cervical tissue was obtained with Boston Children’s Hospital (BCH)
and Harvard Medical School (HMS) Human Investigational Review Board
approval from healthy donors undergoing hysterectomy for benign conditions
and was prepared as previously described (Wheeler et al., 2011, 2013).
BLT Mouse Experiments
Animal work was approved by the Animal Care and Use Committees of Mas-
sachusetts General Hospital, BCH and HMS. All in vivo experiments were per-
formed using progesterone-treated, ketamine/xylazine anesthetized NOD/
SCID/IL2rg/ (NSG) female mice, bearing humanized bone marrow following
reconstitution with CD34+ cells from human fetal liver and surgical human
thymic grafts (BLT mice), prepared by the MGH Humanized Mouse Program
as previously described (Brainard et al., 2009; Kumar et al., 2008; Wheeler
et al., 2011, 2013). Uniform HIV infection in challenge experiments was ob-
tained by requiring high levels of human immune reconstitution using previ-
ously described criteria (Wheeler et al., 2011, 2013). These criteria included
a minimum of 25% of human CD45+ cells in the blood, of which at least
50% are lymphocytes (and at least 40% of these are T cells). The absolute
number of human T cells was required to be at least 200/100 ml of blood.
BLT mice were treated with PBS or 80 pmol of CD4-AsiCs in PBS by atrau-
matic application to the vaginal mucosa in 15 ml according to the indicated
schedule. For infections, HIVJR-CSF (10
5 TCID50) diluted in 10 ml PBS was
applied atraumatically to the vaginal mucosa. Mice were kept supine for
5 min after each application. For some experiments 1 mg/ml of LPS (List Bio-
logical Laboratories) was applied IVAG. For other experiments, rIFN (R&D Sys-
tems) was administered either by tail vein injection (10,000 IU in 50 ml PBS) or
by IVAG administration (2,000 IU in 10 ml PBS). For all post-treatment analysis,
both the vaginal tissue and peripheral blood were harvested and processed as
previously described (Wheeler et al., 2011, 2013). Single cell suspensions were
stained using 1/100 dilutions of hCD45 and hCD4 antibodies (BioLegend) and
sorted by FACS for gene expression analysis.
Additional experimental methods are described in the Supplemental Exper-
imental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.04.048.
AUTHOR CONTRIBUTIONS
J.L., L.A.W., and R.T. designed the research plan and wrote the manuscript.
L.A.W. and R.T. performed experiments with assistance of V.V., N.B., X.L.,
B.B., L.O., S.M., and S.R. A.D.L. and A.M.T. supervised and helped design
the humanized mouse experiments.
ACKNOWLEDGMENTS
This work was supported by grants from the NIH (AI102816 and AI090671 to
J.L.; AI078897 to A.M.T. and A.D.L.), the Harvard CFAR (AI060354 to A.M.T.
and A.D.L.), the Ragon Institute (to J.L., A.M.T., and A.D.L.), and fellowships1726 Cell Reports 15, 1715–1727, May 24, 2016from the Cancer Research Institute, the Adelstein Fund, the Harvard Medical
School MD/PhD Program and the Point Foundation (to L.A.W.), and the Har-
vard CFAR (P30 AI060354 to R.T.). We thank T. Allen and T. Dudek and the
Virology Core of the Ragon Institute for providing viral stocks for in vivo studies
and E. Oliva, M. Miri, and A. Bodo, MGH Surgical Pathology, and L. Yang,
BIDMC, for tissue specimens.
Received: November 3, 2015
Revised: March 21, 2016
Accepted: April 9, 2016
Published: May 12, 2016
REFERENCES
Agy,M.B., Acker, R.L., Sherbert, C.H., and Katze,M.G. (1995). Interferon treat-
ment inhibits virus replication in HIV-1- and SIV-infected CD4+ T-cell lines by
distinct mechanisms: evidence for decreased stability and aberrant process-
ing of HIV-1 proteins. Virology 214, 379–386.
Arfi, V., Rivie`re, L., Jarrosson-Wuille`me, L., Goujon, C., Rigal, D., Darlix, J.L.,
and Cimarelli, A. (2008). Characterization of the early steps of infection of pri-
mary blood monocytes by human immunodeficiency virus type 1. J. Virol. 82,
6557–6565.
Bergamaschi, A., and Pancino, G. (2010). Host hindrance to HIV-1 replication
in monocytes and macrophages. Retrovirology 7, 31.
Boasso, A., Hardy, A.W., Anderson, S.A., Dolan, M.J., and Shearer, G.M.
(2008). HIV-induced type I interferon and tryptophan catabolism drive T cell
dysfunction despite phenotypic activation. PLoS ONE 3, e2961.
Brainard, D.M., Seung, E., Frahm, N., Cariappa, A., Bailey, C.C., Hart, W.K.,
Shin, H.S., Brooks, S.F., Knight, H.L., Eichbaum, Q., et al. (2009). Induction of
robust cellular andhumoral virus-specificadaptive immune responses in human
immunodeficiency virus-infected humanized BLTmice. J. Virol. 83, 7305–7321.
Cai, X., Chiu, Y.H., and Chen, Z.J. (2014). The cGAS-cGAMP-STING pathway
of cytosolic DNA sensing and signaling. Mol. Cell 54, 289–296.
Caux, C., Ait-Yahia, S., Chemin, K., de Bouteiller, O., Dieu-Nosjean, M.C.,
Homey, B., Massacrier, C., Vanbervliet, B., Zlotnik, A., and Vicari, A. (2000).
Dendritic cell biology and regulation of dendritic cell trafficking by chemokines.
Springer Semin. Immunopathol. 22, 345–369.
Coccia, E.M., Krust, B., and Hovanessian, A.G. (1994). Specific inhibition of
viral protein synthesis in HIV-infected cells in response to interferon treatment.
J. Biol. Chem. 269, 23087–23094.
Collins, K.B., Patterson, B.K., Naus, G.J., Landers, D.V., and Gupta, P. (2000).
Development of an in vitro organ culture model to study transmission of HIV-1
in the female genital tract. Nat. Med. 6, 475–479.
d’Ettorre, G., Ceccarelli, G., Giustini, N., Mastroianni, C.M., Silvestri, G., and
Vullo, V. (2014). Taming HIV-related inflammation with physical activity: a mat-
ter of timing. AIDS Res. Hum. Retroviruses 30, 936–944.
Davis, K.A., Lin, Y., Abrams, B., and Jayasena, S.D. (1998). Staining of cell
surface human CD4 with 20-F-pyrimidine-containing RNA aptamers for flow
cytometry. Nucleic Acids Res. 26, 3915–3924.
Dieu-Nosjean, M.C., Vicari, A., Lebecque, S., and Caux, C. (1999). Regulation
of dendritic cell trafficking: a process that involves the participation of selective
chemokines. J. Leukoc. Biol. 66, 252–262.
Fitzgerald-Bocarsly, P., and Jacobs, E.S. (2010). Plasmacytoid dendritic cells
in HIV infection: striking a delicate balance. J. Leukoc. Biol. 87, 609–620.
Gao, D., Wu, J., Wu, Y.T., Du, F., Aroh, C., Yan, N., Sun, L., and Chen, Z.J.
(2013). Cyclic GMP-AMP synthase is an innate immune sensor of HIV and
other retroviruses. Science 341, 903–906.
Gilboa-Geffen, A., Hamar, P., Le, M.T.N., Wheeler, L.A., Trifonova, R., Pet-
rocca, F., Wittrup, A., and Lieberman, J. (2015). Gene Knockdown by EpCAM
Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their
Tumor-Initiating Cells. Mol. Cancer Ther. 14, 2279–2291.
Goldfeld, A.E., Birch-Limberger, K., Schooley, R.T., and Walker, B.D. (1991).
HIV-1 infection does not induce tumor necrosis factor-alpha or interferon-
beta gene transcription. J. Acquir. Immune Defic. Syndr. 4, 41–47.
Haase, A.T. (2010). Targeting early infection to prevent HIV-1 mucosal trans-
mission. Nature 464, 217–223.
Hansen, K., Prabakaran, T., Laustsen, A., Jørgensen, S.E., Rahbæk, S.H.,
Jensen, S.B., Nielsen, R., Leber, J.H., Decker, T., Horan, K.A., et al. (2014). Lis-
teria monocytogenes induces IFNb expression through an IFI16-, cGAS- and
STING-dependent pathway. EMBO J. 33, 1654–1666.
Hardy, G.A., Sieg, S.F., Rodriguez, B., Jiang, W., Asaad, R., Lederman, M.M.,
and Harding, C.V. (2009). Desensitization to type I interferon in HIV-1 infection
correlates with markers of immune activation and disease progression. Blood
113, 5497–5505.
Hasan, M., Koch, J., Rakheja, D., Pattnaik, A.K., Brugarolas, J., Dozmorov, I.,
Levine, B., Wakeland, E.K., Lee-Kirsch, M.A., and Yan, N. (2013). Trex1 regu-
lates lysosomal biogenesis and interferon-independent activation of antiviral
genes. Nat. Immunol. 14, 61–71.
H€ubner, W., Chen, P., Del Portillo, A., Liu, Y., Gordon, R.E., and Chen, B.K.
(2007). Sequence of human immunodeficiency virus type 1 (HIV-1) Gag local-
ization and oligomerization monitored with live confocal imaging of a replica-
tion-competent, fluorescently tagged HIV-1. J. Virol. 81, 12596–12607.
Jackson, A.L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J.,
Johnson, J.M., Lim, L., Karpilow, J., Nichols, K., et al. (2006). Position-specific
chemical modification of siRNAs reduces ‘‘off-target’’ transcript silencing.
RNA 12, 1197–1205.
Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K., and MacLachlan,
I. (2005). Sequence-dependent stimulation of the mammalian innate immune
response by synthetic siRNA. Nat. Biotechnol. 23, 457–462.
Klatt, N.R., Bosinger, S.E., Peck, M., Richert-Spuhler, L.E., Heigele, A., Gile,
J.P., Patel, N., Taaffe, J., Julg, B., Camerini, D., et al. (2014). Limited HIV infec-
tion of central memory and stem cell memory CD4+ T cells is associated with
lack of progression in viremic individuals. PLoS Pathog. 10, e1004345.
Kumar, P., Ban, H.S., Kim, S.S., Wu, H., Pearson, T., Greiner, D.L., Laouar, A.,
Yao, J., Haridas, V., Habiro, K., et al. (2008). T cell-specific siRNA delivery sup-
presses HIV-1 infection in humanized mice. Cell 134, 577–586.
Kumar, A., Abbas, W., and Herbein, G. (2014). HIV-1 latency in monocytes/
macrophages. Viruses 6, 1837–1860.
Lahaye, X., Satoh, T., Gentili, M., Cerboni, S., Conrad, C., Hurbain, I., El Mar-
jou, A., Lacabaratz, C., Lelie`vre, J.D., and Manel, N. (2013). The capsids of
HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate
sensor cGAS in dendritic cells. Immunity 39, 1132–1142.
Lehmann, C., Lafferty, M., Garzino-Demo, A., Jung, N., Hartmann, P., Fa¨tken-
heuer, G., Wolf, J.S., van Lunzen, J., and Romerio, F. (2010). Plasmacytoid
dendritic cells accumulate and secrete interferon alpha in lymph nodes of
HIV-1 patients. PLoS ONE 5, e11110.
McNamara, J.O., 2nd, Andrechek, E.R., Wang, Y., Viles, K.D., Rempel, R.E.,
Gilboa, E., Sullenger, B.A., and Giangrande, P.H. (2006). Cell type-specific
delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005–
1015.
Miller, C.J., Li, Q., Abel, K., Kim, E.Y., Ma, Z.M., Wietgrefe, S., La Franco-
Scheuch, L., Compton, L., Duan, L., Shore, M.D., et al. (2005). Propagation
and dissemination of infection after vaginal transmission of simian immunode-
ficiency virus. J. Virol. 79, 9217–9227.
Monroe, K.M., Yang, Z., Johnson, J.R., Geng, X., Doitsh, G., Krogan, N.J., and
Greene, W.C. (2014). IFI16 DNA sensor is required for death of lymphoid CD4
T cells abortively infected with HIV. Science 343, 428–432.
Olesen, R., Wahl, A., Denton, P.W., and Garcia, J.V. (2011). Immune reconsti-
tution of the female reproductive tract of humanized BLT mice and their sus-
ceptibility to human immunodeficiency virus infection. J. Reprod. Immunol.
88, 195–203.
Orzalli, M.H., Broekema, N.M., Diner, B.A., Hancks, D.C., Elde, N.C., Cristea,
I.M., and Knipe, D.M. (2015). cGAS-mediated stabilization of IFI16 promotes
innate signaling during herpes simplex virus infection. Proc. Natl. Acad. Sci.
USA 112, E1773–E1781.Parrish, N.F., Gao, F., Li, H., Giorgi, E.E., Barbian, H.J., Parrish, E.H., Zajic, L.,
Iyer, S.S., Decker, J.M., Kumar, A., et al. (2013). Phenotypic properties of
transmitted founder HIV-1. Proc. Natl. Acad. Sci. USA 110, 6626–6633.
Piguet, V., and Steinman, R.M. (2007). The interaction of HIV with dendritic
cells: outcomes and pathways. Trends Immunol. 28, 503–510.
Poli, G., Biswas, P., and Fauci, A.S. (1994). Interferons in the pathogenesis
and treatment of human immunodeficiency virus infection. Antiviral Res. 24,
221–233.
Rasaiyaah, J., Tan, C.P., Fletcher, A.J., Price, A.J., Blondeau, C., Hilditch, L.,
Jacques, D.A., Selwood, D.L., James, L.C., Noursadeghi, M., and Towers, G.J.
(2013). HIV-1 evades innate immune recognition through specific cofactor
recruitment. Nature 503, 402–405.
Saba, E., Grivel, J.C., Vanpouille, C., Brichacek, B., Fitzgerald, W., Margolis,
L., and Lisco, A. (2010). HIV-1 sexual transmission: early events of HIV-1 infec-
tion of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal
Immunol. 3, 280–290.
Sandler, N.G., Bosinger, S.E., Estes, J.D., Zhu, R.T., Tharp, G.K., Boritz, E.,
Levin, D., Wijeyesinghe, S., Makamdop, K.N., del Prete, G.Q., et al. (2014).
Type I interferon responses in rhesus macaques prevent SIV infection and
slow disease progression. Nature 511, 601–605.
Shirazi, Y., and Pitha, P.M. (1992). Alpha interferon inhibits early stages
of the human immunodeficiency virus type 1 replication cycle. J. Virol. 66,
1321–1328.
Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP syn-
thase is a cytosolic DNA sensor that activates the type I interferon pathway.
Science 339, 786–791.
Swiecki, M., and Colonna, M. (2010). Unraveling the functions of plasmacytoid
dendritic cells during viral infections, autoimmunity, and tolerance. Immunol.
Rev. 234, 142–162.
Unterholzner, L., and Bowie, A.G. (2008). The interplay between viruses and
innate immune signaling: recent insights and therapeutic opportunities. Bio-
chem. Pharmacol. 75, 589–602.
Wang, Y., Abel, K., Lantz, K., Krieg, A.M., McChesney, M.B., and Miller, C.J.
(2005). The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9
agonist, CpG ODN, induce antiviral cytokines and chemokines but do not
prevent vaginal transmission of simian immunodeficiency virus when applied
intravaginally to rhesus macaques. J. Virol. 79, 14355–14370.
Wheeler, L.A., Trifonova, R., Vrbanac, V., Basar, E., McKernan, S., Xu, Z.,
Seung, E., Deruaz, M., Dudek, T., Einarsson, J.I., et al. (2011). Inhibition of
HIV transmission in human cervicovaginal explants and humanizedmice using
CD4 aptamer-siRNA chimeras. J. Clin. Invest. 121, 2401–2412.
Wheeler, L.A., Vrbanac, V., Trifonova, R., Brehm, M.A., Gilboa-Geffen, A.,
Tanno, S., Greiner, D.L., Luster, A.D., Tager, A.M., and Lieberman, J. (2013).
Durable knockdown and protection from HIV transmission in humanized
mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol. Ther.
21, 1378–1389.
Wu, L., and KewalRamani, V.N. (2006). Dendritic-cell interactions with HIV:
infection and viral dissemination. Nat. Rev. Immunol. 6, 859–868.
Yan, N., Cherepanov, P., Daigle, J.E., Engelman, A., and Lieberman, J. (2009).
The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog. 5,
e1000327.
Yan, N., Regalado-Magdos, A.D., Stiggelbout, B., Lee-Kirsch, M.A., and
Lieberman, J. (2010). The cytosolic exonuclease TREX1 inhibits the innate
immune response to human immunodeficiency virus type 1. Nat. Immunol.
11, 1005–1013.
Zhang, Z., Schuler, T., Zupancic, M., Wietgrefe, S., Staskus, K.A., Reimann,
K.A., Reinhart, T.A., Rogan, M., Cavert, W., Miller, C.J., et al. (1999). Sexual
transmission and propagation of SIV and HIV in resting and activated CD4+
T cells. Science 286, 1353–1357.
Zhang, R., Bloch, N., Nguyen, L.A., Kim, B., and Landau, N.R. (2014). SAMHD1
restricts HIV-1 replication and regulates interferon production in mouse
myeloid cells. PLoS ONE 9, e89558.Cell Reports 15, 1715–1727, May 24, 2016 1727
